SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Address of principal executive offices and zip code)
telephone number, including area code:
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐.
|Item 7.01||Regulation FD Disclosure|
On May 10, 2021, PolarityTE, Inc., issued a press release titled “PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint.” A copy of the press release is furnished with this filing as Exhibit 99.1.
As stated in the press release, the results from the trial will be issued via a poster presentation entitled, “Topline Results: 100 Patient Randomized Controlled Trial to Evaluate the Treatment of Diabetic Foot Ulcers with a Novel Autologous Heterogeneous Skin Construct,” at the Symposium on Advanced Wound Care (SAWC) Spring Conference held virtually May 10-14, 2021. A copy of the poster is furnished with this filing as Exhibit 99.2.
|Item 9.01||Financial Statements and Exhibits.|
|99.1||Press release dated May 10, 2021, titled “PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint.”|
|99.2||Poster titled “Topline Results: 100 Patient Randomized Controlled Trial to Evaluate the Treatment of Diabetic Foot Ulcers with a Novel Autologous Heterogeneous Skin Construct.”|
|104||Cover Page Interactive Data File, formatted in Inline XBRL|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: May 10, 2021||/s/ Jacob Patterson|
|Interim Chief Financial Officer|